SBIR Phase II: Voice-based telehealth interface for symptom monitoring and screening for chronic and acute respiratory diseases

SBIR 第二阶段：基于语音的远程医疗界面，用于慢性和急性呼吸道疾病的症状监测和筛查

• 批准号: 2213110
• 负责人: Satya Venneti
• 金额: $ 100万
• 依托单位: DEEPCONVO INC.
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2213110&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Voice; based

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is a voice-based telehealth interface deployed on mobile devices for symptom monitoring and screening for respiratory diseases. This technology may improve the quality of respiratory care and could prevent costly hospitalizations by delivering monitoring and exacerbation warnings to healthcare providers and patients. Chronic and acute respiratory diseases affect over 70 million Americans and 1 billion people globally. This technology may help improve patient outcomes and save on patient care costs. The proposed project will further develop the existing Chronic Obstructive Respiratory Disease (COPD) Early Exacerbation warning system to measure the earliest deterioration in a patient’s respiratory system through voice and breath data captured through mobile phones. The research objectives include (1) productizing lung function measurement by improving algorithms for measuring lung function in varied real-world environments and on datasets reflective of the target population of patients with respiratory conditions in the US; (2) productizing exacerbation prediction by further training the proof-of-concept algorithm with true respiratory exacerbations resulting in hospitalizations, emergency department visits, and prescription of new or increased medication and treatments; (3) developing and launching a direct-to-patient product with the goals of learning how to most effectively engage the patient to drive usage, communicating effectively with the patient, and bridging the gap between patient and provider to provide timely and effective interventions; and (4) exploring additional use cases by testing products with patients who suffer from varied lung diseases.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这一小型企业创新研究（SBIR）第二阶段项目的更广泛影响/商业潜力是部署在移动的设备上的基于语音的远程医疗界面，用于呼吸道疾病的症状监测和筛查。这项技术可以提高呼吸护理的质量，并通过向医疗保健提供者和患者提供监测和加重警告来防止昂贵的住院治疗。慢性和急性呼吸道疾病影响着7000多万美国人和全球10亿人。这项技术可以帮助改善患者的治疗效果，并节省患者的护理成本。拟议项目会进一步发展现有的慢性阻塞性呼吸系统疾病（COPD）早期恶化预警系统，透过移动的电话收集病人的声音和呼吸数据，量度病人呼吸系统的最早恶化情况。研究目标包括（1）通过改进用于在各种真实世界环境中以及在反映美国呼吸疾病患者目标人群的数据集上测量肺功能的算法，生产肺功能测量;（2）通过用导致住院、急诊科就诊的真实呼吸恶化进一步训练概念验证算法来生产恶化预测，以及新的或增加的药物和治疗处方;（3）开发和推出直接面向患者的产品，目标是学习如何最有效地吸引患者来推动使用，与患者进行有效沟通，并弥合患者和提供者之间的差距，以提供及时有效的干预措施;以及（4）通过在患有各种肺部疾病的患者身上测试产品来探索其他用例。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。